Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTI-1100
- Development stage
- Preclinical
- Lead developer
- Onconaut Therapeutics
- Modality
- Small Molecules
01
Overview
OTI-1100 is a preclinical-stage small molecule inhibitor of Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L), also known as ALC1. Developed by Onconaut Therapeutics, the drug targets the chromatin remodeling activity of CHD1L, which is frequently amplified or overexpressed in various malignancies, including hepatocellular carcinoma and other solid tumors. CHD1L plays a pivotal role in DNA repair pathways and maintaining genomic integrity; its inhibition is intended to trigger apoptosis in cancer cells that are dependent on its activity, representing a targeted approach to treating high-dependency tumors.
02
Targets
CHD1L (Chromodomain-helicase-DNA-binding protein 1-like)
Beyond the preview
Go deeper on OTI-1100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTI-1100.